The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

NCT05061628 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

176

Enrollment

OTHER

Sponsor class

Conditions

Advanced Tumors

Interventions

DRUG: JS006 as Monotherapy
DRUG: JS006 in combination with Toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.